The overall aim of the study is: To provide accurate and reliable information regarding NSCLC clinical management across Central Eastern European countries and Russia in order to detect unmet medical needs of this disease in terms of: * Patient and hospital characteristics. * Diagnostic and treatment approaches: initial and subsequent. * Follow-up patterns in clinical management. * Outcomes: symptoms, death, functionality, quality of life. * Use of resources and burden on patients and health care systems. Addendum objective is to collect epidemiological data on EGFR mutation status (M+, M-) in the Russian population
Study Type
OBSERVATIONAL
Enrollment
840
Research Site
Barnaul, Altaiskiy Krai, Russia
Research Site
Birobidzhan, EAO, Russia
Research Site
Khabarovsk, Khabarovskiy Krai, Russia
Research Site
Khanty-Mansyisk, Khanty-Mansyiskyi AO, Russia
Research Site
Krasnodar, Krasnodarskiy Krai, Russia
Research Site
Vladivostok, Primorskiy Krai, Russia
Research Site
Kazan', Resp. of Tatarstan, Russia
Research Site
Yakutsk, Sakha, Russia
Research Site
Arkhangelsk, Russia
Research Site
Belgorod, Russia
...and 21 more locations
To assess the differences in patient characteristics, disease stage (differentiating between non-advanced disease, locally advanced disease, metastatic disease), and in clinical management across Central Eastern European countries and Russia
Time frame: 24 months
To detect differences in clinical outcomes and related factors among countries
Time frame: 24 months
To identify factors associated with clinical outcomes (patient, disease stage -see above- and clinical management related factors): predictive modelling for improved patient outcome
Time frame: 24 months
To identify factors associated with the different levels of functional status and quality of life
Time frame: 24 months
To compare the use of health care resources among countries
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.